Join us for an insightful 60-minute session with our panel to:
Register Below
Speaker
Biography
Speaker
Nancy Santilli, PNP, MN, FAAN
Epilepsy Consultant
Sunnyvale, CA
Biography
Ms. Nancy Santilli is currently an Epilepsy Consultant. Previously, she served as the Global Managing Director of Human Care Systems, Inc and has worked at Endo Health Solutions (Chadds Ford, PA), Elan Pharmaceuticals (Dublin, Ireland), and the University of Virginia School of Medicine (Charlottesville, VA) where she was the Associated Director of the Comprehensive Epilepsy Program and Associate Professor of Neurology, School of Medicine.
Ms. Santilli earned her MSN degree and NP certification from the University of Virginia in Charlottesville, and she received her BSN from Seton Hall University in South Orange, NJ.
Ms. Santilli has held numerous leadership positions. She is the Chair Emeritus of the Healthcare Businesswomen’s Association, Past President of the Epilepsy Foundation, and Past Treasurer of the American Epilepsy Society. She secured and led multiple clinical trials evaluating new therapies for epilepsy. She is well published, having authored 37 articles and chapters, 50 abstracts, and two books. She is a Fellow of the American Academy of Nursing and a recipient of the International League Against Epilepsy Ambassador Award.
Speaker
Biography
Speaker
Brittani Ireland, DNP
Patient Services Manager; Pediatric Nurse Practitioner
Neurelis, Inc.
Memphis, TN
Biography
Brittani has over 14 years of experience in caring for patients with epilepsy. She began her career as a nurse at Le Bonheur Children’s Hospital, a Level 4 Comprehensive Epilepsy Center. She earned her Doctor of Nursing Practice and became a certified pediatric nurse practitioner in 2016. She has most recently worked as a nurse practitioner at Le Bonheur Children’s Hospital in the neurology clinic and with the neurology inpatient team for almost 6 years.
Brittani’s work as a nurse and nurse practitioner has given her an understanding of how to advocate for patients and families affected by epilepsy. Navigating the challenges of the “epilepsy world” can be overwhelming, and Brittani is passionate about alleviating that stress and making a meaningful impact in the lives of patients and their families.
Speaker
Speaker
Esteban G
Patient Ambassador with episodes of frequent seizures
Speaker
Speaker
Danielle L
Patient Ambassador with episodes of frequent seizures
Making Minutes Matter with VALTOCO® (diazepam nasal spray)
Indication
VALTOCO® (diazepam nasal spray) is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (ie, seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 2 years of age and older.
IMPORTANT SAFETY INFORMATION
WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS
- Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death.
- The use of benzodiazepines, including VALTOCO, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death.
- The continued use of benzodiazepines may lead to clinically significant physical dependence. Although VALTOCO is indicated only for intermittent use, if used more frequently than recommended, abrupt discontinuation or rapid dosage reduction of VALTOCO may precipitate acute withdrawal reactions, which can be life-threatening.
Adverse Reactions
The most common adverse reactions (at least 4%) were somnolence, headache, and nasal discomfort.
Diazepam, the active ingredient in VALTOCO, is a Schedule IV controlled substance.
To report SUSPECTED ADVERSE REACTIONS, contact Neurelis, Inc. at 1-866-696-3873 or FDA at 1-800-FDA-1088 (www.fda.gov/medwatch)
Please see full Prescribing Information, including Boxed Warning.
US-PRC-25-00262-v2 04/2026